Testing a new form of infliximab for Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with Crohn's disease.
- Your Crohn's is moderate to severe, with ulcers in your intestine seen during a scope.
- You've tried and not responded to, or had side effects from, steroids, certain immune drugs, or other biologic treatments.
- You have not had infliximab before (either by IV or injection).
- You are not pregnant, breastfeeding, or planning to become pregnant in the next 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
This study tests if switching from a high-dose infliximab IV infusion to a daily or weekly injection under the skin works just as well. It is for people with inflammatory bowel disease who are already stable on IV infliximab.
This study measures how infliximab (a medicine that calms immune inflammation) moves through the body in children with Crohn’s disease. It mainly helps doctors understand dosing and drug levels, especially when treatment is newly starting.
This trial uses a computer model to study how the body processes infliximab (a medicine that reduces inflammation) in people with Crohn's disease or ulcerative colitis. It aims to find the best dose to help control symptoms.
This study tests whether switching from an IV infliximab to a subcutaneous (under-the-skin) version is safe and works well for people with moderate to severe Crohn's disease. It's for people who have never used a biologic and need a new treatment option.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
Hear when a new Inflammatory Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.